Embolic strokes of undetermined source: a clinical consensus statement of the ESC Council on Stroke, the European Association of Cardiovascular Imaging and the European Heart Rhythm Association of the ESC

George Ntaios,Helmut Baumgartner,Wolfram Doehner,Erwan Donal,Thor Edvardsen,Jeff S Healey,Bernard Iung,Hooman Kamel,Scott E Kasner,Eleni Korompoki,Babak B Navi,Christian Pristipino,Luca Saba,Renate B Schnabel,Emma Svennberg,Gregory Y H Lip

DOI: https://doi.org/10.1093/eurheartj/ehae150

IF: 39.3

2024-05-01

European Heart Journal

Abstract:One in six ischaemic stroke patients has an embolic stroke of undetermined source (ESUS), defined as a stroke with unclear aetiology despite recommended diagnostic evaluation. The overall cardiovascular risk of ESUS is high and it is important to optimize strategies to prevent recurrent stroke and other cardiovascular events. The aim of clinicians when confronted with a patient not only with ESUS but also with any other medical condition of unclear aetiology is to identify the actual cause amongst a list of potential differential diagnoses, in order to optimize secondary prevention. However, specifically in ESUS, this may be challenging as multiple potential thromboembolic sources frequently coexist. Also, it can be delusively reassuring because despite the implementation of specific treatments for the individual pathology presumed to be the actual thromboembolic source, patients can still be vulnerable to stroke and other cardiovascular events caused by other pathologies already identified during the index diagnostic evaluation but whose thromboembolic potential was underestimated. Therefore, rather than trying to presume which particular mechanism is the actual embolic source in an ESUS patient, it is important to assess the overall thromboembolic risk of the patient through synthesis of the individual risks linked to all pathologies present, regardless if presumed causally associated or not. In this paper, a multi-disciplinary panel of clinicians/researchers from various backgrounds of expertise and specialties (cardiology, internal medicine, neurology, radiology and vascular surgery) proposes a comprehensive multi-dimensional assessment of the overall thromboembolic risk in ESUS patients through the composition of individual risks associated with all prevalent pathologies.

cardiac & cardiovascular systems

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the diagnosis and prevention of Embolic Stroke of Undetermined Source (ESUS). ESUS refers to ischemic stroke in which, despite the recommended diagnostic evaluation, no convincing root cause (such as atrial fibrillation, high - degree atherosclerotic plaque, etc.) can be clearly identified. The overall cardiovascular risk of this type of stroke is very high, and the cumulative probability of stroke recurrence in patients within 5 years is 29%, and the probability of other cardiovascular events is 38%. Therefore, it is crucial to optimize secondary prevention strategies to prevent recurrent strokes and other cardiovascular outcomes.

The main objective of the paper is to provide a comprehensive multi - dimensional assessment method to evaluate the overall thromboembolic risk of patients when facing ESUS patients. This includes synthesizing the individual risks of all existing pathological conditions, regardless of whether these pathologies are considered to have a causal relationship with ESUS. Specifically, the paper proposes the following points:

1. **Define ESUS**: Clearly define the definition and diagnostic criteria of ESUS and distinguish it from cryptogenic stroke.
2. **Multi - dimensional assessment**: Through a multidisciplinary expert panel (including professionals in cardiology, internal medicine, neurology, radiology, and vascular surgery), propose a comprehensive multi - dimensional assessment method covering six major potential thromboembolic sources: extracardiac atherosclerosis, patent foramen ovale (PFO) and other right - to - left shunts, left atrial disease, left ventricular disease, valvular heart disease, and cancer.
3. **Risk characteristics**: Describe in detail the risk characteristics of each potential thromboembolic source, for example:
- **Extracardiac atherosclerosis**: Including acute or recent intra - plaque hemorrhage, thin or ruptured fibrous cap, intraluminal thrombus, ulcerated plaque morphology, etc.
- **PFO and other right - to - left shunts**: Including recent deep vein thrombosis or pulmonary embolism, PFO with atrial septal aneurysm or large shunt, RoPE score, etc.
- **Left atrial disease**: Including spontaneous atrial contrast, tricuspid valve malformation, etc.
- **Left ventricular disease**: Including large or dyskinetic scar tissue, left ventricular aneurysm, left ventricular non - compaction, etc.
- **Valvular heart disease**: Including Barlow mitral valve disease, severe mitral valve calcification, aortic valve calcification, etc.
- **Cancer**: Including cardiac vegetations, ISTH overt disseminated intravascular coagulation score, etc.

4. **Clinical practice and research**: Discuss the potential impact of these assessment methods on clinical practice and future research, and point out the knowledge gaps that need further research.

In summary, this paper aims to help doctors more accurately identify and manage the overall thromboembolic risk of ESUS patients through a comprehensive assessment method, thereby optimizing secondary prevention strategies and reducing the occurrence of stroke recurrence and other cardiovascular events.